Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Gastrointestinal stromal tumours; Liposarcoma; Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 03 Oct 2017 Status changed from suspended to recruiting.
- 20 Jun 2017 Planned number of patients changed from 84 to 110.
- 10 Jun 2017 Biomarkers information updated